Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.
Wendt MD, Rockway TW, Geyer A, McClellan W, Weitzberg M, Zhao X, Mantei R, Nienaber VL, Stewart K, Klinghofer V, Giranda VL. Wendt MD, et al. Among authors: geyer a. J Med Chem. 2004 Jan 15;47(2):303-24. doi: 10.1021/jm0300072. J Med Chem. 2004. PMID: 14711304
Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.
Bruncko M, McClellan WJ, Wendt MD, Sauer DR, Geyer A, Dalton CR, Kaminski MA, Weitzberg M, Gong J, Dellaria JF, Mantei R, Zhao X, Nienaber VL, Stewart K, Klinghofer V, Bouska J, Rockway TW, Giranda VL. Bruncko M, et al. Among authors: geyer a. Bioorg Med Chem Lett. 2005 Jan 3;15(1):93-8. doi: 10.1016/j.bmcl.2004.10.026. Bioorg Med Chem Lett. 2005. PMID: 15582418
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A, Filzen GF, Flynn D, Bigge CF, Chen J, Davis JA, Dudley DA, Edmunds JJ, Esmaeil N, Geyer A, Heemstra RJ, Jalaie M, Ohren JF, Ostroski R, Ellis T, Schaum RP, Stoner C. Casimiro-Garcia A, et al. Among authors: geyer a. J Med Chem. 2011 Jun 23;54(12):4219-33. doi: 10.1021/jm200409s. Epub 2011 May 26. J Med Chem. 2011. PMID: 21557540
P2Y1 receptor antagonists as novel antithrombotic agents.
Pfefferkorn JA, Choi C, Winters T, Kennedy R, Chi L, Perrin LA, Lu G, Ping YW, McClanahan T, Schroeder R, Leininger MT, Geyer A, Schefzick S, Atherton J. Pfefferkorn JA, et al. Among authors: geyer a. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3338-43. doi: 10.1016/j.bmcl.2008.04.028. Epub 2008 Apr 15. Bioorg Med Chem Lett. 2008. PMID: 18445527
Pan-KRAS inhibitors BI-2493 and BI-2865 display potent anti-tumor activity in tumors with KRAS wild-type allele amplification.
Tedeschi A, Schischlik F, Rocchetti F, Popow J, Ebner F, Gerlach D, Geyer A, Santoro V, Boghossian AS, Rees MG, Ronan MM, Roth JA, Lipp J, Samwer M, Gmachl M, Kraut N, Pearson M, Rudolph D. Tedeschi A, et al. Among authors: geyer a. Mol Cancer Ther. 2024 Dec 23. doi: 10.1158/1535-7163.MCT-24-0386. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39711431
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer.
Jung P, Glaser SP, Han J, Popa A, Pisarsky L, Feng N, Geyer A, Haderk F, Alpar D, Bristow C, Schmittner S, Traexler PE, Mahendra M, Poehn B, Gandhi P, Fiorelli R, Awate S, Budano N, Martin F, Albrecht C, Drobits-Handl B, Anand SS, Kasturirangan S, Trapani F, Schweifer N, Marszalek JR, Tontsch-Grunt U, Pearson M, Heffernan TP, Kraut N, Vellano CP, García-Martínez JM. Jung P, et al. Among authors: geyer a. MAbs. 2024 Jan-Dec;16(1):2438173. doi: 10.1080/19420862.2024.2438173. Epub 2024 Dec 9. MAbs. 2024. PMID: 39654063 Free PMC article.
314 results